Equities
  • Price (EUR)73.50
  • Today's Change0.50 / 0.68%
  • Shares traded45.00
  • 1 Year change-16.48%
  • Beta1.0652
Data delayed at least 15 minutes, as of Feb 06 2026 07:07 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions with a focus on improving the quality of life of patients with musculoskeletal disorders. The Company offers a portfolio of differentiated technologies that are used to treat a variety of musculoskeletal conditions. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the conditions affecting the spine, including degenerative conditions, deformities, tumors, and trauma. It provides solutions that facilitate both open and minimally invasive surgery techniques. It includes traditional fusion implants, such as pedicle screws and rod systems, and others. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip.

  • Revenue in USD (TTM)2.77bn
  • Net income in USD423.78m
  • Incorporated2003
  • Employees5.30k
  • Location
    Globus Medical Inc2560 General Armistead AveAUDUBON 19403-5214United StatesUSA
  • Phone+1 (610) 930-1800
  • Fax+1 (302) 636-5454
  • Websitehttps://www.globusmedical.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
GMED:NYQ since
announced
Transaction
value
Nevro CorpDeal completed06 Feb 202506 Feb 2025Deal completed-4.97%252.53m
Data delayed at least 15 minutes, as of Feb 06 2026 21:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.